Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00134
|
|||||
| Drug Name |
Folic acid
|
|||||
| Synonyms |
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid; Acfol (Spain); Acide folique [INN-French]; Acidefolique; Acido folico; Acido folico [INN-Spanish]; Acidum folicum; Acidum folicum [INN-Latin]; Acifolic; Antianemia factor; Apo-Folic; BIF0608; Cytofol; Dosfolat B activ; F0043; FOL; Facid; Factor U; Folacid; Folacin; Folaemin; Folaemin [Netherlands]; Folan; Folasic (Australia); Folate; Folbal; Folcidin; Folcidin (VAN); Folcysteine; Foldine; Foldine [France]; Folettes; Foliamin; Folic; Folic acid (JP15/USP/INN); Folic acid (TN); Folic acid [BAN:INN:JAN]; Folic acid [INN:BAN:JAN]; Folic acid dihydrate; Folicet; Folicet (TN); Folico; Folico (Italy); Folina; Folina (Italy); Folipac; Folsaeure; Folsan; Folsaure; Folsav; Folvite; Folvron; Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L; Incafolic; Kyselina listova; Kyselina listova [Czech]; LiverLactobacillus casei factor; Millafol; Mission prenatal; Mittafol; N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo-yl)-L-glutamic acid; N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid; N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid; N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid; Nifolin; Nifolin [Denmark]; Novofolacid; Novofolacid [Canada]; PGA (VAN); PteGlu; Pteroyl-L-glutamic acid; Pteroyl-L-monoglutamic acid; Pteroylglutamic acid; Pteroylmonoglutamate; Pteroylmonoglutamic acid; Serum Folate Level; Usaf cb-13; Vitamin B11; Vitamin B9; Vitamin Bc; Vitamin Be; Vitamin M
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Vitamin deficiency [ICD11: 5B55-5B7Z] | Approved | [1] | |||
| Therapeutic Class |
Vitamins
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C19H19N7O6
|
|||||
| Canonical SMILES |
C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N
|
|||||
| InChI |
InChI=1S/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s1
|
|||||
| InChIKey |
OVBPIULPVIDEAO-LBPRGKRZSA-N
|
|||||
| CAS Number |
CAS 59-30-3
|
|||||
| Pharmaceutical Properties | Molecular Weight | 441.4 | Topological Polar Surface Area | 209 | ||
| Heavy Atom Count | 32 | Rotatable Bond Count | 9 | |||
| Hydrogen Bond Donor Count | 6 | Hydrogen Bond Acceptor Count | 10 | |||
| XLogP |
-1.1
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10318222
, 10321330
, 11112150
, 11335669
, 11360908
, 11364275
, 11366837
, 11369399
, 11371658
, 11375360
, 11377561
, 11461880
, 11485093
, 11489275
, 11490565
, 11493565
, 11495195
, 11537760
, 14857129
, 14930521
, 16028504
, 16077361
, 22389272
, 24845192
, 24894950
, 24894973
, 24894977
, 24894979
, 26612259
, 26680757
, 26704619
, 3787
, 584223
, 7847138
, 7887399
, 7887539
, 7979297
, 8144505
, 8149795
, 8153763
, 829573
, 831381
, 831592
, 831633
, 831664
, 834516
, 835597
, 835744
, 837196
, 841329
|
|||||
| ChEBI ID |
ChEBI:27470
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| FLOT1 | Transporter Info | Folate transporter 1 | Substrate | [3] | ||
| MFT | Transporter Info | Mitochondrial folate transporter/carrier | Substrate | [4] | ||
| MRP1 | Transporter Info | Multidrug resistance-associated protein 1 | Substrate | [5] | ||
| MRP2 | Transporter Info | Multidrug resistance-associated protein 2 | Substrate | [6] | ||
| MRP3 | Transporter Info | Multidrug resistance-associated protein 3 | Substrate | [7] | ||
| MRP4 | Transporter Info | Multidrug resistance-associated protein 4 | Substrate | [8] | ||
| MRP5 | Transporter Info | Multidrug resistance-associated protein 5 | Substrate | [9] | ||
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [10] | ||
| PCFT | Transporter Info | Proton-coupled folate transporter | Substrate | [11] | ||
| SNAT3 | Transporter Info | Sodium-coupled neutral amino acid transporter 3 | Substrate | [12] | ||
| Drug-Transporter Activity Data | ||||||
| Drug-Transporter Activity Data | MRP3 | Transporter Info | Km = 1960 microM | Human embryonic kidney cells (HEK293)-MRP3 | [7] | |
| MRP4 | Transporter Info | Km = 170 microM | Spodoptera frugiperda (Sf9) cells-MRP4 | [8] | ||
| MRP5 | Transporter Info | Km = 1000 microM | Human embryonic kidney cells (HEK293)-MRP5 | [9] | ||
| References | ||||||
| 1 | Folic acid was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9. | |||||
| 3 | Biology of the major facilitative folate transporters SLC19A1 and SLC46A1. Curr Top Membr. 2014;73:175-204. | |||||
| 4 | Polymorphism of SLC25A32, the folate transporter gene, is associated with plasma folate levels and bone fractures in Japanese postmenopausal women. Geriatr Gerontol Int. 2014 Oct;14(4):942-6. | |||||
| 5 | Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1). Biochem Pharmacol. 2004 Apr 15;67(8):1541-8. | |||||
| 6 | Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207. | |||||
| 7 | Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32. | |||||
| 8 | Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 2002 Jun 1;62(11):3144-50. | |||||
| 9 | The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Res. 2005 May 15;65(10):4425-30. | |||||
| 10 | Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31. | |||||
| 11 | Characterization of uptake of folates by rat and human blood-brain barrier endothelial cells. Biofactors. 2010 May-Jun;36(3):201-9. | |||||
| 12 | Purification of recombinant human N-acetyltransferase type 1 (NAT1) expressed in E. coli and characterization of its potential role in folate metabolism. Biochem Pharmacol. 1995 Jun 16;49(12):1759-67. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.